OSCR
Oscar Health, Inc. · Healthcare · Medical - Healthcare Plans
Momentum inputs (comparable managers):
holder breadth +15.8% ·
share flow +7.4% ·
net new positions +9.1%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2.63M | $81.23M | n/a | n/a |
| Q2 2026 | 123 | +14 | 137.19M | $3.91B | +21 | −6 |
| Q1 2026 | 111 | -1 | 110.57M | $1.27B | +11 | −13 |
| Q4 2025 | 112 | -3 | 121.38M | $1.74B | +2 | −4 |
| Q3 2025 | 22 | +3 | 74.59M | $1.41B | +5 | −3 |
| Q2 2025 | 17 | -1 | 57.51M | $1.23B | +1 | −2 |
| Q1 2025 | 15 | -1 | 25.41M | $333.18M | +2 | −3 |
| Q4 2024 | 16 | -1 | 29.22M | $392.74M | +2 | −3 |
| Q3 2024 | 16 | +2 | 34.05M | $722.32M | +2 | n/a |
| Q2 2024 | 14 | n/a | 28.60M | $452.40M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 20.16M | +2.1% | $381.64M | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (passive) | 16.19M | +2.7% | $306.41M | 0.0% | ▲ Add | 2 | SEC ↗ ×14 |
| 3 | State Street Global Advisors ✦ (passive) | 5.13M | -5.0% | $97.15M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | JPMorgan Chase ✦ | 4.95M | n/a | $93.77M | 0.0% | n/c | 1 | SEC ↗ ×10 |
| 5 | Morgan Stanley ✦ | 4.77M | n/a | $90.30M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 6 | Geode Capital Management ✦ (passive) | 4.68M | +3.9% | $88.64M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 4.29M | +113.5% | $81.16M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Capital World Investors ✦ | 3.62M | 0.0% | $68.58M | 0.0% | Held | 6 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 3.00M | +340.9% | $56.78M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 10 | Goldman Sachs Group ✦ | 2.21M | n/a | $41.86M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 11 | D. E. Shaw & Co. ✦ | 1.59M | +74.2% | $30.04M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 12 | Marshall Wace ✦ | 1.14M | +3796.6% | $21.54M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 13 | Millennium Management ✦ | 625.99K | +8.7% | $11.85M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 14 | Adage Capital Partners ✦ | 503.25K | New | $9.53M | 0.0% | New | 1 | SEC ↗ |
| 15 | Point72 Asset Management ✦ | 427.31K | New | $8.09M | 0.0% | New | 1 | SEC ↗ |
| 16 | Glenview Capital ✦ | 408.22K | New | $7.73M | 0.2% | New | 1 | SEC ↗ |
| 17 | Wellington Management ✦ | 359.43K | New | $6.80M | 0.0% | New | 1 | SEC ↗ ×3 |
| 18 | Two Sigma Investments ✦ | 277.34K | -79.7% | $5.25M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 19 | AQR Capital Management ✦ | 107.03K | -43.7% | $2.03M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 20 | Soros Fund Management ✦ | 92.10K | New | $1.74M | 0.0% | New | 1 | SEC ↗ |
| 21 | Fidelity (FMR) ✦ | 37.64K | -90.6% | $712,472 | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 22 | Gotham Asset Management ✦ | 20.10K | -14.5% | $380,493 | 0.0% | ▼ Trim | 6 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $9.53M | 0.0% |
| Point72 Asset Management | $8.09M | 0.0% |
| Glenview Capital | $7.73M | 0.2% |
| Wellington Management | $6.80M | 0.0% |
| Soros Fund Management | $1.74M | 0.0% |
Exited
| Renaissance Technologies | $31.40M | was 0.0% |
| Baillie Gifford | $17.63M | was 0.0% |
| Norges Bank | $358,434 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1 holders, 84.20K shares, $965 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 25.00K sh · $806,000
Officer · 958 sh · $30,129
Officer · 10.36K sh · $325,822
Officer · 9.09K sh · $285,943
Director · 31.42K sh · $988,222
Officer · 28.87K sh · $907,930
Director · 150.00K sh · $4.62M
Director · 600.00K sh · $18.20M
Officer · 18.75K sh · $595,125
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
1.7% of class · View original SEC filing ↗